Member Info for elrico

Bel,

Q1/Q2/Q3/Q4/Q5 & Q6 : are typical rearview Q’s that have been addressed previously.

I guess you’re just insisting on make your points over again just in case we missed them the first dozen times.

TC,

If you have any specific questions, email me. I'll do my best to get them answered.

"Big Bet" should be viewed as a significant clue to the importance of SkinBiotix in the eyes of Croda's strategy. Another below is worth repeating. It is not just about the anti-ageing lysate. - the collaboration is much more significant.
https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-004

Arnaud Fournial, Managing Director of Sederma, said: “The SkinBiotix technology has a solid scientific foundation which attracted us in the first place. We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market. We look forward to a fully collaborative partnership with the SkinBioTherapeutics team and seeing SkinBiotix being embraced by our global partners as a key ingredient across various products to protect and rejuvenate skin.”

TC,

Dear friend, you'll need to walk me through that logic. Cross revenues have no bearing on the acquisition, it's a buyout.

We need to be patient here because we have no idea when the DD started, or when negotiations started. All we have is a clue (if you believe my waffle ) the fundraiser provided a clue both parties have passed a critical stage. I.e; implied agreement on the value. Of course, this hypothesis implies there is no further placing. I find this doubtful because there was no urgency to raise working capital.

Remember, SBTX has a very small team working around the clock spinning plates.

I will be doing an interview with Stuart when there is something new to discuss. Neither of us wishes to go over old ground, it looks desperate.

The EV transition is beset with a range of issues, not least the supply of lithium and other minerals, and infrastructure.

There are a few editorials you may finds useful. Pros and cons.

https://knowledge.sharescope.co.uk/author/elric-langton/

Let’s put it this way. I’m pretty sure of my research on the target. Nothing other than what SBTX has said officially. So confident, I’ve cleared a bit of deadwood in my SIPP and taken profits elsewhere and added yesterday, and again today.

If the acquisition falls at the final hurdle, it’s a setback for the short term. However, IF I am correct, a significant moment for the SBTX that MUST result in a significant rerate in the Company’s prospects. Some of the negative (often fair and reasonable) will be forgiven.

A PLC's CEO's job is not restricted to building a profitable business its shareholder benefit from; it is also a crafting enthusiasm for the investment community. There was once a chorus of enthusiasm from most investors, many waxing lyrically over Stuart's "refreshing enthusiastic delivery" during podcasts recorded with me. Now, though, the SP decline encourages another spin. Are we not odd creatures!!

Engaging with investors is particularly tricky, especially on the AIM cesspit, because there is a thirst for news. If there is drought, and there often is with SBTX, we always end up with heated discussions because some investors, such as me, feel some comments are unhelpful and usually have a sinister motive. I find the remuneration comments particularly distasteful, not least because this topic is constantly regurgitated during a news drought. And always, the same culprits ignore critical points.

1: SOH negotiated the package
2: Stuart took a significant salary reduction to come to SBTX
3: Pay peanuts, you get a monkey - and the monkey eats the nuts
4: Ah, well! :)

SBTX has issued one "official" forecast agreed by the NOMAD, which was promptly unwound, much to the annoyance of everyone, not least because it wasn't clear why until I probed. SBTX has not recovered from this misstep...yet! In hindsight, I would agree neither NSF nor the AxisBiotix product launch ambitious sales figures should have been kept under wraps. But, myself and TW were attempting to probe for encouraging events in a bid to maintain interest. I am sure many would be delighted if they sold and made a bag or three. Sadly, some investors arrived much later.

We have all agreed to invest in a fledgling Company with new science and develop new markets. And yet we are surprised when progress is slower than we expected. SBTX is a risky investment, with critical milestones seemingly de-risking the Company along the way, but there is still some way to go.

SkinBiotix is exceptionally important, but it is a long-term project with multiple revenue stream potential. However, IF, I am right, then the proposed acquisition will surprise investors in a good way, and those selling now will likely be paying a significant premium if they want their shares back.

Cold shower now. :)

Aqua,

You’ll need to explain to me why SBTX has missed the boat with their oral care product? There’s always a first, and it’s rarely the end of the product developments.

How many versions of mouthwashes and toothpaste products are there? There’s always another boat, with a new captain and a new destination.

It is a sad fact some people will regurgitate old and tired topics. NFP, Stuart's salary, share options, and Croda delay, blah, blah, blah; all have been discussed countless times, but some people will persist in regurgitating over and over. It is not as though it is a new investor on a fact-finding mission, but it is not; it is the same people, time and again. It makes me suspicious of motives.

Now, look what you have done...I've turned into Victor Meldrew. :)

Back in a few weeks.

No he hasn’t. Stuart is providing updates in-line with what Croda allow. That’s not deception.

Aqua,

That RNS was related to 600 litres. Croda needed to build a 20,000 litre vessel and test it. That is a different timeline. It’s was around September 2022 the 20,000 confirmed the same findings.

Bel,

I am lost in how you arrived at 15 months claim for the enhancement claims. Can you explain your timeline? I agree with Toyins timeline, which needs Croda to produce the scientific paper to back any additional claims in preparation for Sederma's marketing claims, which will be based on scientific evidence. They are clear margin advantages that Croda explained to SBTX, so why rush them!!

These significant events are outside SBTX's control. Unfortunately, the tail does not wag the dog.

I understand previous disappointments beset the mindset with further disappointments. However, this constant rearview vision often men you miss the excitement in front.

If the team gets the acquisition over the line, I strongly suspect there will be a clamour for SBTX stock. Had you spent more time acting on the clues provided by Stuart and arrived at the same finding as I BELIEVE I have, you would be far more optimistic...assuming I am correct. Frankly, I am astonished that the acquisition has not dominated the discussions.

I get there is a chance the acquisition falls on its ass, many do, even at the final hurdle, but there is a discussion to be had, and we are not having it because we are banging on and on about the same old tires discussions.

I think we have just learned there isn't a great deal of stock around. I had 4x10s, and someone had 15k - seemingly almost enough to turn a 5% deficit, notwithstanding the closing spread.

I do agree news is needed; otherwise, traders get itchy trigger fingers as FOMO on other no-brainer opportunities. Anyway, my sofa needed sorting out! :)

The sofa is far comfier now.

Mol,

Ref the link to the Substack chat. It is open source for people that have downloaded the app. Second, my readers are prioritised.

You imply; the Company has written off c250k of stock. Where is the evidence for this? IMHO, I expect the stock approaching BB will be sold via offers we are seeing in national papers and other promotions; OPTI does this every few months for its online portfolio because it nearly always overstocks. Don't confuse this statement with criticism of OPTI; it's part of growing a brand. Companies tend to overstock rather than not have the ability to grow.

You request, "Please try not to continue to link resolution 6 to the potential acquisition."

I am not; I am taking my cue from the RNS, which buried the acquisition as a mere footnote, and more importantly, the Q&A I had with Stuart.

You also request, "please also stop trying to suggest that the potential acquisition will transform SBTX overnight."

You are not the first person to misquote me. I do not believe I said the acquisition would transform SBTX overnight. However, I believe it will transform SBTX, and for the record, this will happen overnight...there you go! Why? *Because I believe the target Company is profitable. Also, any acquisition would need to be accretive to SBTX. Think about those two comments for a while, please. Then, on these...

- SBTX will overnight become a Company that has acquired a dozen or so products it can back its IP into and double its product portfolio.
- Has established routes in national pharmacies and the NHS.
- Establish synergies between the two
- Revenues will remove all conspiracies of light-out placing
- SBTX becomes either BE or, more likely, profitable - on current spending
- An established marketing team which appears to be good at what it does
- Expand the acquired portfolio beyond the UK shores

Mol, assuming the quick points above are correct, how would you describe the enlarged group?

I am prepared to be wrong, but I have spent many hours pouring over Companies house, the target product portfolio, the location, etc., with the clues we have, and therefore reasonably confident I have narrowed the target down to a couple of Companies. The danger is to speculate beyond what I have already, so I have kept this to a minimum for our sanity and reduced the number of eggs directed my way, especially if there is an egg shortage; we don't want to waste them on me. :)

*There are assumptions I have successfully identified the target and that the accounts are accurate.
In addition, acquisitions have a habit of falling at the final hurdle because someone seeks to push the envelope too far. So, there is a danger it does not complete.

Shoppers are raving over a supplement that they insist has helped ease up skin discomfort and our readers can bag an exclusive 50% off with code EXPRESS50. https://open.substack.com/chat/posts/61c13436-4ece-4c58-95d5-b93b1060c5c0?utm_source=share

Repetitional damaging. https://twitter.com/lemminginvestor/status/1621477146785980417?s=46&t=ZcYyMMVNB7PRLmvEqfyF-w

Not in the context of previous RNS, Mol.

Indeed, Toyin.

https://open.substack.com/chat/posts/61c13436-4ece-4c58-95d5-b93b1060c5c0?utm_source=share

...you will make the same mistake? OPTI's reduction is due to what?

Correction regarding Seneca. The is a fund, therefore the reporting threshold is 10/5%, not the typical 1%. I think Seneca has increased from 6.9% to 9.5%.